Interestingly, it has been observed that the combination of an immune checkpoint inhibitor (anti-PD1) with the NOX1 inhibitor GKT771 (Genkyotex) displayed an additional antitumor effect in an experimental model of colon carcinoma [63,64], thereby opening new perspectives for the use of NOX1 inhibitors as an adjuvant therapeutic option in solid tumors, including HCC. The gene discussed is NOX1; the disease is hepatocellular carcinoma.